Skip to content

Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy

Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06356233
Acronym
FIMBEX
Enrollment
10
Registered
2024-04-10
Start date
2024-05-01
Completion date
2027-12-31
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STXBP1 Encephalopathy With Epilepsy

Keywords

STXBP1

Brief summary

This is a prospective observational study to evaluate the phenotype of 10 patients under 10 years of age with developmental epileptic encephalopathy due to mutation of the STXBP1 gene. The study will consist of a clinical and neurodevelopmental evaluation, magnetic resonance imaging, prolonged electroencephalogram, cardiological study, and analysis of biomarkers in cerebrospinal fluid. These patients will be followed up for 3 years. The aim of the study is, knowing the baseline phenotype, to analyse the response to commonly used drugs and to anticipate the response to different drugs available on the market in this group of patients based on clinical and biomarker assessment (EEG, MRI and study of specific proteins and neurotransmitters in plasma, urine and CSF).

Interventions

No intervention will be performed

Sponsors

Fundación Iniciativa para las Neurociencias (FINCE)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 10 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients under 10 years of age with confirmed mutation for STXBP1. In cases where the diagnostic technique for the mutation is not optimal, a trio exome will be performed to confirm the mutation.

Exclusion criteria

* Presence of functional disability that prevents the neuropsychological study from being carried out and absence of a reliable informant for the patient.

Design outcomes

Primary

MeasureTime frame
CSF biomarkersBaseline, 1 year and 2 years
EEG markersBaseline, 1 year and 2 years
MRI markersBaseline, 1 year and 2 years

Secondary

MeasureTime frame
Clinical phenotypeBaseline, 1 year and 2 years

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026